Interferon- Therapy in Multiple Sclerosis: Evidence for a Clinically Relevant Dose Response

ISSN： 0012-6667

Source： Drugs, Vol.61, Iss.12, 2001-01, pp. : 1693-1703

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Managing the Adverse Effects of Interferon- Therapy in Multiple Sclerosis

By Bayas A. Rieckmann P.

Drug Safety, Vol. 22, Iss. 2, 2000-02 ,pp. : 149-159

Adis International

Access to resources Recommend Favorite

Development of interferon-β as a therapy for multiple sclerosis

By Markowitz Clyde

Expert Opinion on Emerging Drugs, Vol. 9, Iss. 2, 2004-11 ,pp. : 363-374

Informa Healthcare

Access to resources Recommend Favorite

Interferon-Beta Therapy Monitoring in Multiple Sclerosis Patients

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 9, Iss. 1, 2009-03 ,pp. : 14-28

Bentham Science Publishers

Access to resources Recommend Favorite

Dose and Frequency of Administration of Interferon- Affect its Efficacy in Multiple Sclerosis

By Sharief M.K.

Clinical Drug Investigation, Vol. 23, Iss. 9, 2003-01 ,pp. : 551-559

Adis International

Access to resources Recommend Favorite

Benefit-risk assessment of interferon-b therapy for relapsing multiple sclerosis

By Francis Gordon

Expert Opinion on Drug Safety, Vol. 3, Iss. 4, 2004-07 ,pp. : 289-303

Informa Healthcare

Access to resources Recommend Favorite